Great Biotech Quotes

Richard Davidson who is a neuroscientist at the University of Wisconsin has expertise in the brain and emotion, and he’s found in his research that when we’re agitated, when we are upset and angry and anxious, there’s a lot of activity in the right prefrontal area, just behind the forehead, also the amygdala, the brain’s trigger point for the fight-flight-freeze response, when we’re on the other hand in a really positive state, I feel great, enthusiastic, what a wonderful day, there’s a lot of activity on the left side and no activity on the right side, each of us have a ratio at rest of right-to-left activity that predicts our mood range day to day. He finds there’s a bell curve for this like for IQ, most of us are in the middle, we have bad days, we have good days, if you’re very far to the right you may be clinically depressed or clinically anxious, if you’re very far to the left, you’re very resilient, you bounce right back from setbacks. So Davidson paired up with a fella named Jon Kabat-Zinn who has made mindfulness, as he calls it, very popular, for example, in the medical sector, as a way to manage chronic conditions, and also in the states of business recently, a lot of businesses are bringing it in, and it’s more or less what we just did. Davidson and Kabat-Zinn went to a biotech start-up, a 24/7 you know high pressure environment and they taught people how to do mindfulness which is more or less the exercise of watching the breath, but they did it 30 minutes a day, for 8 weeks. What he found was that before that people’s brains were tilted to the right, they’re pretty hassled and stressed, after eight weeks, 30 minutes a day, they were tilting back towards the left and what’s very interesting is people spontaneously started saying: “Hey, you know, I’m starting to enjoy my work again, I remember what I love about this job”. In other words the positive mood was really making a difference.

Many of the best biotech and pharma companies today have learned to separate the roles of inventor and champion. They train people for the project champion job—the Deak Parsons skill-set—and elevate their authority. It goes against the grain. On the creative side, inventors (artists) often believe that their work should speak for itself. Most find any kind of promotion distasteful. On the business side, line managers (soldiers) don’t see the need for someone who doesn’t make or sell stuff—for someone whose job is simply to promote an idea internally. But great project champions are much more than promoters. They are bilingual specialists, fluent in both artist-speak and soldier-speak, who can bring the two sides together.

In 1963, Choh Hao Li, chairman and lone tenured faculty member in the Institute of Experimental Biology at Berkeley, announced that he had isolated and purified his sixth pituitary hormone, lipotropin. The magnitude of such a feat is clear considering that only one other person had ever purified a hormone, and that person was not coincidentally a student of Li's. The purification of lipotropin should have been a reason to celebrate; however, Li's colleagues at Berkeley acknowledged but did not rejoice in his success. As they perceived it, endocrinology was a scientific field that came out of the clinical sciences, which meant that Li's research was completely unsound, and they put enormous pressure on him to change his scientific topic. When that did not work, Wendell Stanley tried to 'promote [Li] out of the Virus Laboratory,' then later University Chancellor Clark Kerr threatened to discontinue the Institute for Experimental Biology because it did not fit with Berkeley's commitment to pure research. Things got infinitely worse for Li, of course, because he became perceived as less qualified with each professional achievement. [...] C. H. Li's travails at Berkeley are only half the story. In 1969, five years after transferring from Berkeley to UCSF, Li and his laboratory assistants assembled a highly complex synthetic version of human growth hormone (HGH) that was biologically active and could promote the growth of bones and muscle tissue. Rather than ignore or criticize the work, however, journalists waxed eloquently [sic] about Li's creation of HGH. One described it as no less than a panacea for most of the world's problems. Others clearly saw specific applications: 'it might now be . . . possible to tailor-make hormones that can inhibit breast cancer.' Li's discovery of synthetic HGH 'constituted a truly . . . great research breakthrough [that had] obvious applications,' ranging from 'human growth and development to . . . treatment of cancer and coronary artery disease.' Desperate letters poured in too; athletes wanted to know if HGH would help them become faster, bigger, stronger, and dwarfs from all over the world begged for samples of HGH or to volunteer as experimental subjects. Unlike at Berkeley, Li's discovery made him a hero at UCSF. None other than UCSF Chancellor Phillip Lee described Li's discovery as 'meticulous, painstaking, and brilliant research' and then tried to capitalize on the moment by asking the public and their political representatives to increase federal support of bioscience research. 'Research money is dwindling fast,' repeated Lee to anyone who cared to listen. 'We've proven than synthesis can be done, now all we need is the money and time to prove its tremendous value.' It is not surprising that federal and state money began to pour into Li's lab. What is shocking, however, is how quickly Li achieved scientific acclaim, not because he changed, but because the rest of the world around him changed so much.

The future is created not by backward looking masses but by forward thinking innovators. In the early 21st century, the train of progress is once again leaving the station, and the author believes this will probably be the last train to ever leave the station of humanity. In order to get on board, you have to understand 21st century technology, in particular biotech and computer algorithms. The main products of the 21st century will be bodies, brains and minds. When genetic engineering and artificial intelligence reveal their full potential, democracy and free markets will become obsolete too.

Kali or Kaali mind and Indra putra are having good cause but, If they are going wrong only way to stop them is Biotech and Only in South India, Engineering Human and Animal mind is under ethics but not completely un ethics, I remember My great Granpa and his hidden palm leaves always, it will be useful when North Indian are going wrong

By far the main stakeholder Shkreli took from was customers – patients and health insurance companies. But Shkreli also took from his colleagues, who may have joined a biotech start-up excited about inventing new drugs, but instead spent their days ordered to squeeze higher profits from existing drugs. He took from suppliers, because the restricted sale and thus production of Daraprim slashed the demand for its inputs. And he took from communities, because reduced access to Daraprim hurt patients, their families and their friends.

The biotech company seemed to follow implicitly, though not explicitly, Louis Pasteur’s adage about creating luck by sheer exposure. “Luck favors the prepared,” Pasteur said, and, like all great discoverers, he knew something about accidental discoveries. The best way to get maximal exposure is to keep researching. Collect opportunities—on that, later.